Breaking AI & Tech News Analyzed

French authorities detained European Parliament member Rima Hassan on Thursday, accusing her of "apology for terrorism" after a social‑media post referenced Kozo Okamoto, a participant in the 1972 Ben Gurion Airport attack. The detention, reported by Le Parisien, marks a rare instance where a sitting MEP’s parliamentary immunity appears to have been set aside. According to the newspaper, Hassan had already removed the contentious post from X, but the investigation continued. Police also reported finding a small quantity of synthetic drugs in her possession during the arrest. Jean‑Luc Mélenchon, founder of the left‑wing La France Insoumise (LFI) party, condemned the move on X, stating, "There is no longer parliamentary immunity in France. Intolerable." He and other LFI colleagues argue the action is designed to silence supporters of Palestine. LFI parliamentarians Sophia Chikirou and Mathilde Panot echoed the criticism, accusing the French police and justice system of being weaponised against activists. Panot warned that President Emmanuel Macron’s France is witnessing a "new level" of criminalisation of political opponents. The controversy follows Hassan’s recent denial of entry to Canada, which she described as censorship, and a prior alert by far‑right National Rally politician Matthias Renault to Paris prosecutors about the same X post. Renault welcomed the detention, calling it "the beginning of the end of impunity for the LFI MP." Hassan, a 33‑year‑old French‑Palestinian lawyer elected to the European Parliament in 2024, is a vocal critic of Israel’s war in Gaza and participated in a Gaza‑bound flotilla intercepted by Israeli forces in October 2025. Her advocacy has repeatedly drawn ire from pro‑Israel groups across Europe. While Hassan and her legal team have not responded to Reuters’ requests for comment, the incident raises broader questions about the balance between anti‑terrorism legislation and political freedoms within the EU, especially as debates over Palestine intensify across the continent.

President Donald Trump has announced a new policy threatening to impose 100% tariffs on US pharmaceutical companies that do not agree to lower their drug prices. This move is part of his effort to address the high cost of prescription medications in the US.The tariffs will specifically target branded drugs and their active ingredients, while generic drugs, which account for over 90% of medicines sold in the US, will be exempt for at least one year. Additionally, certain specialty drugs, such as orphan, veterinary, and other specialty drugs, will be exempt if they are from countries with which the US has a trade deal or meet urgent public health needs.Drugmakers that enter into pricing agreements with the White House and onshore drug production will be exempt from the tariffs. Companies planning to increase their domestic manufacturing will face a 20% tariff that will escalate to 100% over four years.The policy has been met with criticism from industry groups, such as the Midsized Biotech Alliance of America (MBAA), which argues that it creates an "unfair two-tiered system" that benefits large companies with diversified portfolios.Trump has been under pressure to lower drug prices, with US patients often paying nearly triple what patients pay in other developed nations. The announcement comes as the White House faces pressure from consumers to address rising costs amid other tariff-related price increases and high gas prices triggered by geopolitical tensions.

Tiger Woods announced he is pausing his golf career to focus on health and treatment after a police stop near his Jupiter Island, Florida home that led to a DUI suspicion charge.In a statement posted on X, Woods said, "I know and understand the seriousness of the situation I find myself in today. I am stepping away for a period of time to seek treatment and focus on my health. This is necessary in order for me to prioritize my well‑being and work toward lasting recovery." He added that he hopes to return "healthier, stronger, and more focused" and asked for privacy for his family.According to court records released Tuesday, Woods entered a plea of not guilty and has asked for a jury trial. The incident occurred on a residential road when his Land Rover clipped a truck, crossed a double yellow line, and rolled onto its driver’s side, causing roughly $5,000 in property damage to the other vehicle.Deputies observed several signs of impairment, including profuse sweating, bloodshot and glassy eyes, and lethargic speech and movements. Woods told investigators he had not consumed alcohol but had taken "a few" prescription medications, including Vicodin, blood‑pressure medication, and cholesterol medication. A search of his pocket uncovered two hydrocodone pills, a prescription opioid.While Woods refused a urine test for drugs, a breathalyzer showed no alcohol in his system. He was charged with misdemeanor DUI, property damage, and refusal to submit to testing. After a brief hospital clearance, he was held for the mandatory eight‑hour Florida detention period before posting $1,150 bail.Former President Donald Trump commented on the situation, noting Woods’ extensive injury history and stating, "He tested negative for alcohol... He lives a life of pain. He doesn’t have an alcohol problem, but he does have pain." Trump also mentioned Woods’ relationship with his former daughter‑in‑law, Vanessa Trump.Woods’ attorney, Douglas Duncan, filed a waiver of arraignment and a demand for a jury trial, moving his initial court appearance to a docket‑sounding hearing scheduled for May 5. The golfer has not competed in a PGA Tour event since July 2024, though he appeared in the TGL indoor league last week.Prior to the crash, Woods was listed for the US Senior Open and was undecided about playing in the upcoming Masters at Augusta National, leaving his future tournament schedule uncertain.

Kenyan marathon runner Albert Korir, the 2021 New York City Marathon champion, has been handed a five-year doping ban by the Athletics Integrity Unit (AIU). Korir admitted to using a banned performance-enhancing drug, specifically the synthetic form of erythropoietin (EPO), which stimulates red blood cell production.The ban, which runs from January 8 until January 7, 2031, was reduced from six years due to Korir's early admission and acceptance of the sanction. The 32-year-old athlete tested positive during out-of-competition tests in Kenya in October.Korir has had a notable career, winning the 2021 New York marathon in a time of 2 hours, 8 minutes, and 22 seconds. He also came third in the 2023 New York marathon with a personal best time of 2:06:57. Additionally, he won the Ottawa Marathon in 2019 and 2025.This sanction comes as part of Kenya's ongoing efforts to clean up its image in athletics, following a string of doping scandals. Over 140 Kenyan runners, mainly long-distance athletes, have been sanctioned for drugs offences since the 2016 Rio de Janeiro Olympics. Recently, Kenya handed out its first lifetime ban to marathon runner Beatrice Toroitich and a six-year ban to 10km record holder Rhonex Kipruto in June 2024.

Eli Lilly, the US pharmaceutical group behind the Mounjaro weight-loss drug, is seeking to resume its investments in the UK after pausing them last year. The company is in talks with UK ministers to regularly increase NHS drug prices and end a rebate scheme. Patrik Jonsson, president of Eli Lilly's international business, expressed optimism about reaching an agreement this summer.The talks will also explore 'innovative' pricing plans, such as linking payments for anti-obesity drugs to whether the treatment helps patients return to work. This comes as the US pharmaceutical industry increases pressure on the UK, with Keir Starmer agreeing to the first increase in NHS cost-effectiveness thresholds in 27 years. The threshold was raised from £20,000 to £30,000 a year for every year of life gained to £25,000 to £35,000.Eli Lilly was one of several pharmaceutical companies that ditched or paused almost £25bn in planned investments in the UK last year. The company paused its plans to invest in a laboratory site in central London. Jonsson stated that the resumption of Eli Lilly's investment would depend on the outcome of its talks with the government.He emphasized that prices for medicines in the UK had been 'far too low for far too long' and that the threshold couldn't remain static for another three decades. The UK agreed to pay 25% more for new medicines by 2035 as part of a US-UK drug pricing deal, which could eventually reach £9bn a year.Large pharmaceutical companies have protested about a 'rebate' scheme, under which they are required to pay back a chunk of revenue from sales of branded medicines. This scheme is expected to fall in 2026, although Jonsson believes payments 'should actually get down to zero' over time.

Robert F Kennedy Jr, the US health secretary, has unveiled a chaotic and unpredictable agenda for public health policy under his 'Make America Healthy Again' (Maha) initiative. His approach tends to favor personal choice and autonomy over large-scale, mandatory public health interventions, such as childhood vaccine requirements.The Maha agenda has raised concerns over the potential risks associated with injectable peptide drugs. Mr. Kennedy plans to open up the sale of 'about 14' of these drugs to the public, despite the US Food and Drug Administration (FDA) restricting 17 peptides in 2023 due to 'potential significant safety risks'. None of these peptides have been proven to be safe or effective for human use.The peptides in question are often promoted for biological enhancement, such as increasing muscle mass or cognitive benefits, but the evidence for these effects in humans is thin. Reports of people self-administering peptide therapies, usually bought from China 'for research use only', are widespread, particularly in Silicon Valley.The Maha project wants to make the grey market the only market, effectively sanctioning mass public use of unproven treatments. Peptides are clearly drugs and shouldn’t be allowed for widespread use without rigorous clinical trials. Opening loopholes for sale would undermine the precautionary principle that has successfully led public health policy for generations.It is also worth noting that other governments are unlikely to be as cavalier as Mr. Kennedy about peptides. However, people everywhere will continue to call for more personal choice and more bodily autonomy, and those conversations are important. The case for safety, proof, and regulation must be made to ensure that public health policy prioritizes the well-being of individuals.

The UK is on the brink of a medicine shortage crisis, with experts warning that the country is just weeks away from feeling the effects of the ongoing conflict in Iran. The war has already disrupted the supply of essential raw materials, including oil, gas, crop fertiliser, and helium.The pharmaceutical industry, which relies heavily on imports, is particularly vulnerable to these disruptions. India, known as the 'pharmacy of the world', produces a significant proportion of generic drugs and active pharmaceutical ingredients (APIs) used globally. However, with the Strait of Hormuz largely closed due to the conflict, the transportation of these vital supplies is becoming increasingly difficult.Medicine prices are also expected to rise as a result of the conflict. The US-Israel war on Iran has doubled air freight costs, which could make some medicines loss-making to supply to the NHS. While suppliers have long-term pricing agreements with NHS hospitals, they have more flexibility to increase prices for drugs supplied to GP practices and pharmacies.The UK's reliance on imported medicines is significant, with about half of its medicines produced domestically, a third coming from India, and another chunk from the EU. During the Covid pandemic, paracetamol and other painkillers were in short supply in Britain and elsewhere, as drugmakers in India struggled to keep up with demand.Medical distributors typically stock six to eight weeks of supplies to avoid shortfalls, but if the conflict drags on, drug shortages could emerge in only a few weeks' time. Experts warn that the overall ripple effect on the industry is significant, with the patient ultimately picking up the tab, either directly or via public health systems like the NHS.

The UK's Competition and Markets Authority (CMA) has taken a significant step to address concerns over the rising costs of veterinary services. Following a two-and-a-half-year investigation, the CMA has found that the £6.7bn market lacks strong competition, with large chains dominating the industry. As a result, pet owners have faced huge price rises and been left in the dark about bills.The CMA has ordered vets to cap prescription fees at £21 for the first medicine and £12.50 for any additional drugs. This move is expected to save pet owners hundreds of pounds. Additionally, vets must now inform pet owners that medicines may be cheaper online and provide a written estimate in advance for any treatment expected to cost £500 or more.Public satisfaction with the cost of services was found to be low, with the CMA noting that average prices of vet services had risen sharply, by 63%, between 2016 and 2023. The watchdog also found internal documents from some large veterinary groups that linked price increases to an expectation that pet owners would not react by purchasing less or switching away.The CMA has also proposed a cost comparison website to increase competition and drive down costs. Large groups will be required to make clear that individual vet practices are part of a chain, and pet owners can expect to see changes before Christmas, including standard price lists.The measures have been welcomed by some in the industry, with CVS and Vets for Pets expressing their support for the changes. However, the British Veterinary Association president, Rob Williams, noted that delivering highly skilled veterinary medicine is costly and that prices have risen sharply in recent years due to various factors, including higher costs experienced by all businesses.

Scientists have made a groundbreaking discovery that could lead to the development of new obesity drugs. By studying the unique metabolic abilities of pythons, researchers have identified a molecule that appears to play a crucial role in regulating appetite and weight loss. The molecule, called pTOS, was found to increase significantly in the blood of pythons after they eat, and when administered to obese mice, it led to a significant reduction in food intake and a 9% loss of body weight over 28 days. The discovery could lead to the development of new obesity drugs that work in a different way to existing medications, such as GLP-1 medications like Wegovy. Unlike these medications, which can have side effects such as nausea and stomach pain, pTOS appears to act on the brain's appetite centers, reducing food intake without these adverse effects. The researchers, led by Dr. Jonathan Long from Stanford University and Prof. Leslie Leinwand from the University of Colorado Boulder, published their findings in the journal Nature Metabolism. They believe that pTOS, which is naturally produced by the snake's gut bacteria and also found in human urine, could be a safe and effective treatment for obesity. While further research is needed before the findings can be applied clinically, the discovery is seen as a promising step towards the development of new obesity treatments. The study's results suggest that pTOS could be a potential therapeutic target for the treatment of obesity and related metabolic disorders.